Information Provided By:
Fly News Breaks for June 3, 2019
Jun 3, 2019 | 08:40 EDT
Jefferies analyst Biren Amin raised his price target for Iovance Biotherapeutics to $33 from $29 saying the company's data "continue to trend in the right direction" for both melanoma and cervical. The analyst believes biologics license applications could be submitted for both indications in 2020 and he keeps a Buy rating on shares of Iovance.
News For IOVA From the Last 2 Days
There are no results for your query IOVA